STAT3 and primary cutaneous T-cell non-Hodgkin lymphoma: In addition, our data suggest that p-STAT3 levels in these cells are predictive of their sensitivity to specific JAK/STAT inhibitors, thus highlighting a putative role of the miR-124/STAT3 axis as a therapeutic biomarker in CTCL.